ABSTRACT
El carcinoma neuroendocrino de esófago representa menos del 2% de casos de cáncer de esófago. Esta forma de presentación es extremadamente inusual, ya que este tipo de carcinoma se suele presentar con mayor frecuencia en zonas broncopulmonares. Los síntomas suelen asociarse a la obstrucción esofágica e incluyen odinofagia, disfagia y pérdida de peso, siendo infrecuente la clínica de síndrome carcinoide. Para el diagnóstico se requiere de uno o más de los siguientes marcadores de inmunohistoquímica positivos: cromogranina A, sinaptofisina o CD56 positivos, así como la presencia de los anticuerpos EMA y PANCK positivos. Se reporta el caso de un paciente varón con diagnóstico de tumor neuroendocrino de esófago.
Neuroendocrine carcinoma of esophagus represents less than 2% of cases of cancer of the esophagus. This presentation is extremely unusual, as this type of carcinoma typically presents with greater frequency in bronchopulmonary regions. The symptoms are usually associated with esophageal obstruction and include odynophagia, dysphagia and weight loss and are not usually associated with Carcinoid syndrome. The diagnosis requires one or more of the following positive immunohistochemical markers: Chromogranin A, synaptophysin or CD56 positive, as well as the presence of EMA and PANCK positive. We report the case of a male patient with diagnosis of neuroendocrine tumor of esophagus.
Subject(s)
Aged , Humans , Male , Esophageal Neoplasms/diagnosis , Carcinoma, Neuroendocrine/diagnosis , Esophageal Neoplasms/complications , Esophageal Neoplasms/chemistry , Esophageal Neoplasms/diagnostic imaging , Weight Loss , Deglutition Disorders/etiology , Biomarkers, Tumor/analysis , Melena/etiology , Esophagoscopy , Fatal Outcome , Carcinoma, Neuroendocrine/complications , Carcinoma, Neuroendocrine/chemistry , Carcinoma, Neuroendocrine/diagnostic imaging , Tomography, Spiral ComputedABSTRACT
No abstract available.
Subject(s)
Adult , Humans , Male , Adenocarcinoma/chemistry , Antineoplastic Agents/therapeutic use , Biopsy , Carcinoma, Large Cell/chemistry , Carcinoma, Neuroendocrine/chemistry , Carcinoma, Non-Small-Cell Lung/chemistry , Drug Resistance, Neoplasm , Lung Neoplasms/chemistry , Magnetic Resonance Imaging , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Tomography, X-Ray Computed , Treatment Outcome , Biomarkers, Tumor/analysisABSTRACT
Small cell of undifferenciated tumors are present in almost all organs, and it impose the need of performing a differential diagnosis between undifferenciated tumors with residual differentiation according to the type of organ, and the carcinoma of small cells of neuroendocrine origin. The concept of neuroendocrine differentiation (NED) in the prostatic adenocarcinoma has reached considerable attention due to its prognostic and therapeutic implies. Here it is presented a new neuroendocrine prostatic carcinoma case taking care of its hystopathologic diagnosis and evolution.
Los tumores indiferenciados de células pequeñas pueden ser encontrados prácticamente en todos los órganos, imponiendo la necesidad de realizar el diagnóstico diferencial entre tumores indiferenciados con diferenciación residual según el tipo de órgano y el carcinoma de células pequeñas de origen neuroendocrino. El concepto de diferenciación neuroendocrina (DNE) en el adenocarcinoma de próstata ha recibido recientemente considerable atención debido a sus implicancias pronosticas y terapéuticas. Se presenta un nuevo caso de carcinoma neuroendocrino de próstata con consideraciones sobre su diagnóstico histopatológico y su evolución.